A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...

Biogen Inc. (NASDAQ:BIIB), a $20.8 billion ... the United States and Europe are now reviewing a higher dose regimen of nusinersen, a drug designed to treat spinal muscular atrophy (SMA).

Biogen has said it is to file nusinersen for spinal muscular atrophy (SMA) in infants after a phase 3 trial met primary endpoint. Biogen developed the drug in partnership with Ionis, and has ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

Simultaneously, Biogen is under review by the FDA and EMA for a higher dose regimen of the same SMA drug, nusinersen. The company has maintained a positive outlook with an Outperform rating from ...

Royalty also holds rights on Biogen’s MS medication Tysabri (natalizumab) and spinal muscular atrophy drug Spinraza (nusinersen), acquired through agreements with Ionis and Perrigo. The deal ...

Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan.

Biogen Inc. (Nasdaq ... 2/3 DEVOTE study evaluating the safety and efficacy of a higher dose regimen of nusinersen in treatment-naïve, symptomatic infants with spinal muscular atrophy (SMA).

which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq ...